BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23403637)

  • 1. First-in-human phase 0 trial of oral 5-iodo-2-pyrimidinone-2'-deoxyribose in patients with advanced malignancies.
    Kummar S; Anderson L; Hill K; Majerova E; Allen D; Horneffer Y; Ivy SP; Rubinstein L; Harris P; Doroshow JH; Collins JM
    Clin Cancer Res; 2013 Apr; 19(7):1852-7. PubMed ID: 23403637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and Pharmacology Study of Ropidoxuridine (IPdR) as Prodrug for Iododeoxyuridine-Mediated Tumor Radiosensitization in Advanced GI Cancer Undergoing Radiation.
    Kinsella T; Safran H; Wiersma S; DiPetrillo T; Schumacher A; Rosati K; Vatkevich J; Anderson LW; Hill KD; Kunos C; Collins JM
    Clin Cancer Res; 2019 Oct; 25(20):6035-6043. PubMed ID: 31337643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical toxicity and efficacy study of a 14-day schedule of oral 5-iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyuridine radiosensitization in U251 human glioblastoma xenografts.
    Kinsella TJ; Vielhuber KA; Kunugi KA; Schupp J; Davis TW; Sands H
    Clin Cancer Res; 2000 Apr; 6(4):1468-75. PubMed ID: 10778979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Schedule-dependent drug effects of oral 5-iodo-2-pyrimidinone-2'-deoxyribose as an in vivo radiosensitizer in U251 human glioblastoma xenografts.
    Seo Y; Yan T; Schupp JE; Radivoyevitch T; Kinsella TJ
    Clin Cancer Res; 2005 Oct; 11(20):7499-507. PubMed ID: 16243824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of 5-iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyuridine-mediated radiosensitization in mouse and human tissues.
    Kinsella TJ; Kunugi KA; Vielhuber KA; Potter DM; Fitzsimmons ME; Collins JM
    Clin Cancer Res; 1998 Jan; 4(1):99-109. PubMed ID: 9516958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-iodo-2-pyrimidinone-2'-deoxyribose-mediated cytotoxicity and radiosensitization in U87 human glioblastoma xenografts.
    Kinsella TJ; Kinsella MT; Seo Y; Berk G
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1254-61. PubMed ID: 17967315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical study of the systemic toxicity and pharmacokinetics of 5-iodo-2-deoxypyrimidinone-2'-deoxyribose as a radiosensitizing prodrug in two, non-rodent animal species: implications for phase I study design.
    Kinsella TJ; Schupp JE; Davis TW; Berry SE; Hwang HS; Warren K; Balis F; Barnett J; Sands H
    Clin Cancer Res; 2000 Sep; 6(9):3670-9. PubMed ID: 10999760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IPdR: a novel oral radiosensitizer.
    Saif MW; Berk G; Cheng YC; Kinsella TJ
    Expert Opin Investig Drugs; 2007 Sep; 16(9):1415-24. PubMed ID: 17714027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential radiosensitization in DNA mismatch repair-proficient and -deficient human colon cancer xenografts with 5-iodo-2-pyrimidinone-2'-deoxyribose.
    Seo Y; Yan T; Schupp JE; Colussi V; Taylor KL; Kinsella TJ
    Clin Cancer Res; 2004 Nov; 10(22):7520-8. PubMed ID: 15569982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An in vivo comparison of oral 5-iodo-2'-deoxyuridine and 5-iodo-2-pyrimidinone-2'-deoxyribose toxicity, pharmacokinetics, and DNA incorporation in athymic mouse tissues and the human colon cancer xenograft, HCT-116.
    Kinsella TJ; Kunugi KA; Vielhuber KA; McCulloch W; Liu SH; Cheng YC
    Cancer Res; 1994 May; 54(10):2695-700. PubMed ID: 8168099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicology and pharmacokinetic study of orally administered 5-iodo-2-pyrimidinone-2'deoxyribose (IPdR) x 28 days in Fischer-344 rats: impact on the initial clinical phase I trial design of IPdR-mediated radiosensitization.
    Kinsella TJ; Kinsella MT; Hong S; Johnson JP; Burback B; Tosca PJ
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):323-34. PubMed ID: 17562042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.
    Morgan RJ; Newman EM; Doroshow JH; McGonigle K; Margolin K; Raschko J; Chow W; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Carroll M; Vasilev S; Akman S; Coluzzi P; Wagman L; Longmate J; Paz B; Yen Y; Klevecz R
    Cancer Res; 1998 Jul; 58(13):2793-800. PubMed ID: 9661893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of locally advanced cancer of the head and neck with 5'-iododeoxyuridine and hyperfractionated radiation therapy: measurement of cell labeling and thymidine replacement.
    Epstein AH; Lebovics RS; Goffman T; Teague D; Fuetsch ES; Glatstein E; Okunieff P; Cook JA
    J Natl Cancer Inst; 1994 Dec; 86(23):1775-80. PubMed ID: 7966416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer.
    Schilsky RL; Janisch L; Berezin F; Mick R; Vogelzang NJ; Ratain MJ
    Cancer Res; 1993 Mar; 53(6):1293-6. PubMed ID: 7680282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion of 5-iodo-2-pyrimidinone-2'-deoxyribose to 5-iodo-deoxyuridine by aldehyde oxidase. Implication in hepatotropic drug design.
    Chang CN; Doong SL; Cheng YC
    Biochem Pharmacol; 1992 May; 43(10):2269-73. PubMed ID: 1599512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leucovorin modulation of 5-iododeoxyuridine radiosensitization: a phase I study.
    McGinn CJ; Kunugi KA; Tutsch KD; Feierabend C; Alberti D; Lindstrom MJ; Wilding G; Arzoomanian RZ; Kinsella TJ
    Clin Cancer Res; 1996 Aug; 2(8):1299-305. PubMed ID: 9816300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology and phase I/II study of continuous intravenous infusions of iododeoxyuridine and hyperfractionated radiotherapy in patients with glioblastoma multiforme.
    Kinsella TJ; Collins J; Rowland J; Klecker R; Wright D; Katz D; Steinberg SM; Glastein E
    J Clin Oncol; 1988 May; 6(5):871-9. PubMed ID: 2835444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd).
    Galanis E; Goldberg R; Reid J; Atherton P; Sloan J; Pitot H; Rubin J; Adjei AA; Burch P; Safgren SL; Witzig TE; Ames MM; Erlichman C
    Ann Oncol; 2001 May; 12(5):701-7. PubMed ID: 11432631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.